Next Article in Journal
Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites
Next Article in Special Issue
Modulation of the Anti-Tumor Efficacy of Photodynamic Therapy by Nitric Oxide
Previous Article in Journal / Special Issue
Hypericin in the Dark: Foe or Ally in Photodynamic Therapy?
Article Menu

Export Article

Open AccessArticle
Cancers 2016, 8(10), 94;

Mreg Activity in Tumor Response to Photodynamic Therapy and Photodynamic Therapy-Generated Cancer Vaccines

British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada
Author to whom correspondence should be addressed.
Academic Editor: Michael R. Hamblin
Received: 7 August 2016 / Revised: 10 October 2016 / Accepted: 11 October 2016 / Published: 15 October 2016
(This article belongs to the Special Issue Photodynamic Cancer Therapy)
Full-Text   |   PDF [796 KB, uploaded 15 October 2016]   |  


Myeloid regulatory cells (Mregs) are, together with regulatory T cells (Tregs), a dominant effector population responsible for restriction of the duration and strength of antitumor immune response. Photodynamic therapy (PDT) and cancer vaccines generated by PDT are modalities whose effectiveness in tumor destruction is closely dependent on the associated antitumor immune response. The present study investigated whether the immunodepletion of granulocytic Mregs in host mice by anti-GR1 antibody would improve the response of tumors to PDT or PDT vaccines in these animals. Anti-GR1 administration immediately after Temoporfin-PDT of mouse SCCVII tumors abrogated curative effect of PDT. The opposite effect, increasing PDT-mediated tumor cure-rates was attained by delaying anti-GR1 treatment to 1 h post PDT. With PDT vaccines, multiple anti-GR1 administrations (days 0, 4, and 8 post vaccination) improved the therapy response with SCCVII tumors. The results with PDT suggest that neutrophils (boosting antitumor effect of this therapy) that are engaged immediately after photodynamic light treatment are within one hour replaced with a different myeloid population, presumably Mregs that hampers the therapy-mediated antitumor effect. Anti-GR1 antibody, when used with optimal timing, can improve the efficacy of both PDT of tumors in situ and PDT-generated cancer vaccines. View Full-Text
Keywords: photodynamic therapy; cancer vaccines; Mregs; anti-GR1 antibody photodynamic therapy; cancer vaccines; Mregs; anti-GR1 antibody

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Korbelik, M.; Banáth, J.; Zhang, W. Mreg Activity in Tumor Response to Photodynamic Therapy and Photodynamic Therapy-Generated Cancer Vaccines. Cancers 2016, 8, 94.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top